Month: October 2016

Opsona News 3

Opsona receives orphan designation for MDS with OPN-305.

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States Food and Drug Administration for myelodysplastic syndromes (MDS). Myelodysplastic syndromes are a complex and heterogeneous …

Opsona receives orphan designation for MDS with OPN-305. Read More »

Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration (FDA) Investigational Device Exemption (IDE), with Japanese Pharmaceuticals and Medical Devices Agency (PMDA) concurrence under …

Veryan Completes enrolment into the MIMICS-2 clinical study Read More »

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top